menu
    • menu

    Company profile for Vericel Corporation

    NEW Drugs in Dev: 5
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects ...
    Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vericel CorporationUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    64 Sidney Street, Cambridge, MA 02139
    Telephone
    Telephone
    (617) 588-5555
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.vcel.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vericel-corporation
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/VericelCorp

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vericel To Release Q1 2026 Financial Results On May 7
    Vericel To Release Q1 2026 Financial Results On May 7

    23 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/23/3279918/34447/en/vericel-to-report-first-quarter-2026-financial-results-on-may-7-2026.html

    GLOBENEWSWIRE
    23 Apr 2026
    Share Share
    MediWound Reports BARDA Grants Vericel $197M for NexoBrid
    MediWound Reports BARDA Grants Vericel $197M for NexoBrid

    02 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/02/3267793/30505/en/MediWound-Reports-BARDA-Contract-Award-to-Vericel-for-NexoBrid-Valued-at-up-to-197-Million.html

    GLOBENEWSWIRE
    02 Apr 2026
    Share Share
    Vericel Wins BARDA Award Up to $197M for NexoBrid Development
    Vericel Wins BARDA Award Up to $197M for NexoBrid Development

    02 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/02/3267771/34447/en/Vericel-Announces-BARDA-Award-Valued-at-up-to-197-Million-for-Procurement-and-Advanced-Development-of-NexoBrid.html

    GLOBENEWSWIRE
    02 Apr 2026
    Share Share
    Vericel Unveils FDA-Approved Advanced Therapy Facility
    Vericel Unveils FDA-Approved Advanced Therapy Facility

    04 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/04/3249314/34447/en/Vericel-Announces-FDA-Approval-of-New-State-of-the-Art-Advanced-Therapy-Manufacturing-Facility.html

    GLOBENEWSWIRE
    04 Mar 2026
    Share Share
    Vericel To Present At Multiple Upcoming Investor Conferences
    Vericel To Present At Multiple Upcoming Investor Conferences

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/03/3248363/34447/en/Vericel-to-Present-at-Multiple-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share
    Vericel To Release 2025 Financial Results On Feb 26, 2026
    Vericel To Release 2025 Financial Results On Feb 26, 2026

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237182/34447/en/Vericel-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-26-2026.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search